Market Overview:

The global cystic fibrosis therapeutics market size reached US$ 6 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 10.3 Billion by 2027, exhibiting a growth rate (CAGR) of 9.4% during 2022-2027.

Cystic fibrosis (CF) is a rare and progressive genetic disorder that is characterized by an abnormal movement of sodium and chloride across the gastrointestinal and respiratory tracts. This disorder can cause the development of viscous secretions in the lungs, pancreas, intestines and liver. The management and treatment of CF involve physical therapy, gene therapy, physiotherapy and nutritional support. Along with this, gene therapy and medicinal drugs, such as pancreatic enzyme supplements, mucolytics, bronchodilators and cystic fibrosis transmembrane conductance regulator (CFTR) modulators are also used for targeting cellular interactomes and symptomatic improvement. These drugs can be administered to the patient orally or by inhalation.

The rising incidence of cystic fibrosis across the globe, along with improvements in the diagnostic technologies of the disorder, is one of the key factors driving the growth of the market. Furthermore, widespread adoption of cystic fibrosis transmembrane conductance (CFTR) modulators as a treatment alternative is also providing a boost to the market growth. CFTRs are configured to regulate the flow of water and chloride through cell linings of the lungs and other organs and correct the malfunctioning protein in the body. Additionally, various technological advancements, such as the development of personalized drug therapy, molecular prosthetics and innovative drugs with improved efficacy, are acting as another growth-inducing factor. Other factors, including rising healthcare expenditures, increasing health consciousness, and awareness regarding the available treatment options for cystic fibrosis, are projected to drive the market further. 

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cystic fibrosis therapeutics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class, drug molecule type, route of administration and end-user.

Breakup by Drug Class:

• Pancreatic Enzyme Supplements
• Mucolytics
• Bronchodilators
• CFTR Modulators
• Antibiotics
• Others
   

Breakup by Drug Molecule Type:

• Small Molecule Drugs
• Biologics
   

Breakup by Route of Administration:

• Oral Drugs
• Inhaled Drugs
   

Breakup by End-User:

• Hospitals
• Clinics
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alaxia, Alcresta Therapeutics Inc., Allergan, AstraZeneca, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., etc.

Report Coverage:

Key Questions Answered in This Report:

• How has the global cystic fibrosis therapeutics market performed so far and how will it perform in the coming years?
• What are the key regional markets?
• What has been the impact of COVID-19 on the global cystic fibrosis therapeutics market?
• What is the breakup of the market based on the drug class?
• What is the breakup of the market based on the drug molecule type?
• What is the breakup of the market based on the route of administration?
• What is the breakup of the market based on the end-user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global cystic fibrosis therapeutics market and who are the key players?
• What is the degree of competition in the industry?